

**SUBMITTED BY:**

**STEPHEN M. LANIER, PH.D.  
VICE PRESIDENT FOR RESEARCH**

**REPORT ON WAIVERS APPROVED  
TO BOARD STATUTE 2.41.01.140**

**BACKGROUND**

Two research projects required a petition to waive Statute 2.41.01.140 because of review restrictions on publishing the research results. This waiver has been approved by the Vice President for Research to allow acceptance of the relevant grant or contract, acting in accordance with the University's research policy on restricted and proprietary research.

**OVERVIEW**

**Allergan Sales, LLC**

This waiver allowed acceptance of an award funded by Allergan Sales, LLC, a leading pharmaceutical company focused on developing new medicines that address unmet medical needs in critical therapeutic areas as well as increasing global access to high-quality, affordable medicines. The grant, "Clinical and economic comparison of ceftaroline fosfamid versus daptomycin for the treatment of bloodstream infections caused by methicillin resistant *Staphylococcus aureus*," was awarded to Michael J. Rybak, Pharm.D., M.P.H., a faculty member in the Eugene Applebaum College of Pharmacy & Health Sciences. The project is a comparison study of the antibiotic ceftaroline fosfamid versus the antibiotic daptomycin for the treatment of methicillin-resistant *Staphylococcus aureus* bloodstream infection. Rybak and his collaborators will do research to determine if ceftaroline is not inferior to daptomycin for salvage therapy of MRSA bloodstream infections following vancomycin treatment failure. The research is collaborative with Allergan researchers, and they will partake in the study evaluation and be authors on any publication stemming from the research. Therefore, all publications stemming from this project will be a joint effort by WSU and Allergan researchers, and require Allergan participation and approval.

**Allergan Sales, LLC**

This waiver allowed acceptance of a second award funded by Allergan Sales, LLC. The grant, "Pharmacoeconomic analysis of ceftaroline fosfamid for acute bacterial skin and skin structure infections: Focus on those at risk for methicillin-resistant *Staphylococcus aureus*," was awarded to Michael J. Rybak, Pharm.D., M.P.H., a faculty member in the Eugene Applebaum College of Pharmacy & Health Sciences. The project is an economic comparison study of the antibiotic ceftaroline fosfamid versus the antibiotic vancomycin daptomycin for the treatment of complicated acute bacterial skin and skin structure infections. The goal is to see if ceftaroline treatment will result in a 20% decrease in the duration of length of stay post diagnosis of these infections, thus decreasing the overall hospital costs. The research is collaborative with Allergan researchers, and they will partake in the study evaluation and be authors on any publication stemming from the research. Therefore, all publications stemming from this project will be a joint effort by WSU and Allergan researchers, and require Allergan participation and approval.